PTU-110 Reduction in Serum Sodium (NA) in Patients Treated with Terlipressin for Varcieal Bleeding (VB) and Hepatorenal Syndrome (HRS)

    loading  Checking for direct PDF access through Ovid

Abstract

Introduction

Terlipressin is used in the management of VB and HRS. Studies have suggested decrease in Na levels on terlipressin, usually in VB.

Introduction

We set out to report the incidence of fall in serum Na in patients receiving terlipressin for VB or HRS.

Methods

Consecutive patients admitted to Gwent Liver Unit who received terlipressin were identified. Main outcome measure was fall in Na level during and up to 5 days post therapy.

Results

60 patients were analysed (32 HRS, 28 VB). Median Na pre-treatment was 133 and 29/60 (48%) had existing hyponatraemia; 16 (27%) had Na <125mmol/l.

Results

Na fell in 34/60 patients (57%) and was less likely if baseline hyponatraemia existed (38% VS 74% p = 0.004). A fall of ≥5mmol/l occurred in 23%.

Results

Median time to nadir Na was 3 days and time to recovery to pre-treatment Na was 6.5 days. No complications of hyponatremia were observed.

Results

Patients with VB were more likely (vs HRS patients) to have any fall in Na or a ≥5mmol/l reduction (68% vs 47% p = 0.1 and 32% vs 16% p = 0.12 respectively) but failed to reach significance.

Results

Mortality was 22% overall and a fall in Na was actually associated with reduced mortality –9% vs 34% (p = 0.01).

Conclusion

Serum Na falls in >50% receiving terlipressin and a fall ≥5mmol/l noted in 23%.

Conclusion

However, no significant complications occurred and a fall in serum Na was actually associated with improved mortality. Patients with VB treated with terlipressin trended towards a greater likelihood of Na reduction versus those with HRS.

Disclosure of Interest

None Declared.

Related Topics

    loading  Loading Related Articles